Pradaxa Articles
FDA confirms views that Boehringer's Pradaxa bleeding rates no higher than for warfarin
19 March 2013
Positive trials results for Boehringer Ingelheim's Pradaxa for prevention of recurrent DVT and PE
22 February 2013
Brazil's atrial fibrillation market to grow at 31% annually over the next five years
19 December 2012
Australian review finds more work needed on new anticoagulants
19 December 2012
NICE recommends NHS use of Pradaxa
15 March 2012
FDA reviews Pradaxa bleeding risk
8 December 2011
EMA says bleeding risks associated with Boehringer Ingelheim’s Pradaxa can be managed
20 November 2011
UK NICE recommends Boehringer’s Pradaxa for stroke prevention
1 November 2011
Benefits of Boehringer’s Pradaxa come at high cost, study finds
20 October 2011
Atrial fibrillation drug market to increase nearly eight-fold to over $10 billion in 2020
20 October 2011
Australian government U-turn on PBS listing of drugs
3 October 2011
UK’s NICE asks for more info on Boehringer’s Pradaxa; backs Novartis’ Tasigna but not Glivec or B-MS Sprycel for leukemia
18 August 2011
EMA’s CHMP advisory unit decisions include good news for Lilly, Bristol-Myers, Boehringer and Roche
18 April 2011
Boehringer Ingelheim 2010 profits slump, hit by generics, but upbeat on success of Pradaxa
7 April 2011
Boehringer’s anti-clotting drug Pradaxa added to ACC recommendations for treating irregular heartbeat
16 February 2011
Landmark double-blind ROCKET AF study shows Bayer/J&J’s Xarelto is better than warfarin
16 November 2010
US FDA gives thumbs up for Boehringer Ingelheim’s Pradaxa to prevent stroke in people with AF
20 October 2010
US FDA advisory backs Boehringer Ingelheim’s Pradaxa, putting firm ahead in the race to get new blood thinner on US market
21 September 2010
European Commission approves label change for Boehringer Ingelheim’s Viramune; US FDA updates on Pradaxa
17 September 2010
Novel oral anticoagulants will drive venous thromboembolism market to nearly double by 2018
1 April 2010
Showing 1-33 of 33 articles
- 1
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
